Tufts Medical Center Cancer Center
Boston, MA
Not yet accepting
MajesTEC-7
A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)
- Bispecific Antibody
- BCMA
- Randomization
- Phase 3
- Has results
Not currently accepting
Belantamab Mafodotin Combination Therapy
A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combination With Iberdomide (CC-220)/Dexamethasone Versus Belantamab Mafodotin (GSK2857916)/Dexamethasone in Relapsed Refractory Multiple Myeloma
- Antibody Drug Conjugate (ADC)
- BCMA
- Phase 1/2
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trialsAccepting patients
EQUATE
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Monoclonal Antibody
- CD38
- Phase 3
Not currently accepting
MajesTEC-4
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4
- Bispecific Antibody
- BCMA
- Phase 3
1 hidden based on your filters. Show All